Bridged bicyclic inhibitors of menin-MLL and methods of use

US11555041B2 · kind B2 · utility

Assignees

• Kura Oncology, Inc. · US
• THE REGENTS OF THE UNIVERSITY OF MICHIGAN · US

Inventors

• Tao Wu · Carlsbad, US
• Liansheng Li · San Diego, US
• Yi Wang · San Diego, US
• Pingda Ren · San Diego, US
• Jolanta Grembecka · Ann Arbor, US
• Tomasz Cierpicki · Ann Arbor, US
• Szymon Klossowski · Ann Arbor, US
• Jonathan Pollock · Ann Arbor, US
• Dmitry Borkin · Ann Arbor, US

Key dates

• Filing date: Jul 13, 2020
• Grant date: Jan 17, 2023
• Expiry date: Jul 13, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula (I-A) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.